Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent

Biomaterials

Volumn 33, Issue 36, 2012, Pages 9225-9231

  Chandrasekharan, Prashant ^a   Yong, Cai Xian ^a   Poh, Zihan ^a   He, Tao ^b   He, Zhengjie ^c   Liu, Shuang ^c   Robins, Edward G ^a   Chuang, Kai Hsiang ^a   Yang, Chang Tong ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Contrast agent; DO3A conjugated cation; Gadolinium complex; Magnetic resonance imaging (MRI); Tumor targeting

Indexed keywords

CELL UPTAKE; CLINICAL USE; CONTRAST AGENT; DIAGNOSTIC IMAGING; GADOLINIUM COMPLEXES; GD-DOTA; GD-DTPA; HIGH AFFINITY; IN-VITRO; IN-VIVO IMAGING; MOLECULAR PROBES; MRI CONTRAST AGENTS; ORGANIC CATIONS; POSITRON EMISSION; RELAXIVITY; SIGNAL ENHANCEMENT; TUMOR CELLS; TUMOR TARGETING; TUMOR UPTAKE;

CHELATION; MAGNETIC RESONANCE IMAGING; POSITIVE IONS; TUMORS;

GADOLINIUM;

GADOLINIUM CHELATE[DO3A 2 (DIPHENYLPHOSPHORYL)ETHYLDIPHENYLPHOSPHONIUM]; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CONTRAST MEDIA; GADOLINIUM; HELA CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; MICE; ORGANOMETALLIC COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84867401893     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.071     Document Type: Article

References (40)

1. Liberman E.A., Topaly V.P., Tsofina L.M., Jasaitis A.A., Skulachev V.P. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 1969, 222:1076-1078.
2. Pathania D., Millard M., Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 2009, 61:1250-1275.
3. Summerhayes I.C., Lampidis T.J., Bernal S.D., Nadakavukaren J.J., Nadakavukaren K.K., Shepard E.L., et al. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci U S A 1982, 79:5292-5296.
4. Modica-Napolitano J.S., Aprille J.R. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res 1987, 47:4361-4365.
5. Davis S., Weiss M.J., Wong J.R., Lampidis T.J., Chen L.B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 1985, 260:3844-3850.
6. Dairkee S.H., Hackett A.J. Differential retention of rhodamine 123 by breast carcinoma and normal human mammary tissue. Breast Cancer Res Treat 1991, 18:57-61.
7. Modica-Napolitano J.S., Apprille J.R. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 2001, 49:63-70.
8. Duchen M.R. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med 2004, 25:365-451.
9. Mannella C.A. The relevance of mitochondrial membrane topology to mitochondrial function. Biochim Biophys Acta 2006, 1762:140-147.
10. 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging 2007, 34:2057-2065.
11. Min J., Biwal S., Deroose C., Gambhir S. Tetraphenylphosphonium as a novel molecular probe for imaging tumors. J Nucl Med 2004, 45:636-643.
12. 99mTc-MIBI. J Nucl Med 2002, 43:234-238.
13. Yang C.-T., Li Y.X., Liu S. Synthesis and structural characterization of complexes of a DO3A-conjugated triphenylphosphonium cation with diagnostically important metal ions. Inorg Chem 2007, 46:8988-8997.
14. 64Cu-labeled triphenylphophonium and triphenylarsonium cations as highly tumor-selective imaging agents. J Med Chem 2007, 50:5057-5069.
15. 64Cu-labeled triphenylphophonium cations. J Med Chem 2008, 51:2971-2984.
16. 64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics. Bioconjug Chem 2008, 19:2008-2022.
17. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications. Chem Rev 1999, 99:2293-2352.
18. Aime S., Botta M., Terreno E. Gd(III)-based contrast agents for MRI. Adv Inorg Chem 2005, 57:173-237.
19. Caravan P. Strategies for increase the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35:512-523.
20. Yang C.-T., Chuang K.-H. Gd(III) chelates for MRI contrast agents: from high relaxivity to " smart" , from blood pool to blood-brain barrier permeable. MedChemComm 2012, 3:552-565.
21. 254: a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug Chem 2001, 12:587-593.
22. Villaraza A.J.L., Bumb A., Brechbiel M.W. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev 2010, 110:2921-2959.
23. Park J.-A., Lee J.-J., Jung J.-C., Yu D.-Y., Oh C., Ha S., et al. Gd-DOTA conjugate of RGD as potential tumor-targeting MRI contrast agent. ChemBioChem 2008, 9:2811-2813.
24. Corat C., Robert P., Lancelt E., Prigent P., Ballet S., Guilberi I., et al. Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med 2008, 60:1337-1346.
25. Stefania R., Tei L., Barge A., Crich S.G., Szabo I., Cabella C., et al. Tuning glutamine binding modes in Gd-DOTA-based probes for an improved MRI visualization of tumor cells. Chem Eur J 2009, 15:76-85.
26. Aime S., Batta M., Bruce J.I., Mainero V., Parker D., Terreno E. Modulation of the water exchange rates in [Gd-DO3A] complex by formation of ternary complexes with carboxylate ligands. Chem Commun 2001, 115-116.
27. Aime S., Batta M., Fasaro M., Terreno E. Prototropic and water-exchange processes in aqueous solutions of Gd(III) chelates. Acc Chem Res 1999, 32:941-949.
28. Kittigowittana K., Yang C.-T., Cheah W.C., Chuang K.-H., Tuang C.-Y., Chang Y.-T., et al. Development of intravascular contrast agents for MRI using gadolinium chelates. ChemMedChem 2011, 6:781-787.
29. Murphy M.P., Smith R.A.J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007, 47:629-656.
30. Haris M., Gupta R.K., Singh A., Husain N., Husain M., Pandey C.M., et al. Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI. Neuroradiology 2008, 50:531-540.
31. Gossmann A., Okuhata Y., Shames D.M., Helbich T.H., Roberts T.P.L., Wendland M.F., et al. Prostate cancer tumor grade differentiation with dynamic contrast enhance MR imaging in the rats: comparison of macromolecular and small-molecular contrast media-preliminary experience. Radiology 1999, 213:265-272.
32. Akata D., Kerimoglu U., Hazirolan T., Karcaaltincaba M., Köse F., özmen M.N., et al. Efficacy of transvaginal contrast-enhanced MRI in the early staging of cervical carcinoma. Eur Radiol 2005, 15:1727-1733.
33. Ricke J., Sehouli J., Hach C., Hänninen E.L., Lichtenegger W., Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 2003, 13:943-949.
34. Orel S.G., Schnall M.D. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001, 220:13-30.
35. Neeman M., Dafni H. Structural, functional, and molecular MR imaging of the microvasculature. Annu Rev Biomed Eng 2003, 5:29-56.
36. Gillies R.J., Raghunand N., Karczmar G.S., Bhujwalla Z.M. MRI of the tumor microenvironment. J Magn Reson Imaging 2002, 16:430-450.
37. Schirner M., Menrad A., Stephens A., Frenzel T., Hauff P., Licha K. Molecular imaging of tumor angiogenesis. Ann NY Acad Sci 2004, 1014:67-75.
38. Schima W., Mukerjee A., Saini S. Contrast-enhanced MR imaging. Clin Radiol 1996, 51:235-244.
39. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006, 17:2359-2362.
40. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006, 21:1104-1108.